This study aims to evaluate the effect of Folic acid and Vitamin B12 supplementation on Biochemical parameters in subjects with type-2 Diabetes. 80 selected subjects will be divided into 4 groups of 20 each. * Group A: to receive Folic acid 5 mg once daily for 8 weeks along with standard oral anti-diabetic drugs; * Group B: to receive Vitamin B12 500 mcg once daily for 8 weeks along with standard oral anti-diabetic drugs; * Group C: to receive both Folic acid 5 mg once daily and Vitamin B12 500 mcg once daily for 8 weeks along with standard oral anti-diabetic drugs; * Group D: to receive no additional intervention apart from standard oral anti-diabetic drugs. The biochemical parameters will be evaluated before and after the intervention.
This is a randomized, parallel group, open label study to evaluate the effect of Folic acid and Vitamin B12 supplementation on Biochemical parameters in subjects with type-2 Diabetes. 80 selected subjects will be randomly assigned to 4 groups of 20 each as follows: * Group A: to receive Folic acid 5 mg once daily for 8 weeks along with standard oral anti-diabetic drugs; * Group B: to receive Vitamin B12 500 mcg once daily for 8 weeks along with standard oral anti-diabetic drugs; * Group C: to receive both Folic acid 5 mg once daily and Vitamin B12 500 mcg once daily for 8 weeks along with standard oral anti-diabetic drugs; * Group D: to receive no additional intervention apart from standard oral anti-diabetic drugs. The subjects will also be advised to be on a normal routine diet, not to skip any meal and not to change their exercise pattern (if any) during the study period.The compliance of the intervention will be monitored by instructing the patients to return all unused tablets at the end of the 8 weeks period of study. All the subjects will be asked to report after an overnight fasting of 12 hours on two occasions i.e. at the start of the study before allocation of group and 8 weeks after allocation. After measurement of body weight, height and blood pressure (by Mercury Sphygmomanometer), 5 milliliter of early morning fasting venous blood sample will be collected under aseptic measures on both the occasions. The samples collected will then be appropriately processed for the analysis of various biochemical parameters. The results of all the parameters evaluated will be recorded in the subject's Data Collection Form.The data will be analyzed using Statistical Package for the Social Sciences (SPSS) version 21.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
80
tab. Folic acid 5 mg
tab. Vitamin B12 500 mcg
Patients receiving either of the following oral hypoglycemic agents 1. Sulfonylurea 2. Metformin 3. Metformin plus Sulfonylurea
All India Institute of Medical Sciences, Bhubaneswar
Bhubaneswar, Odisha, India
HbA1c
Time frame: 8 weeks
Fasting plasma glucose
Time frame: 8 weeks
Fasting plasma insulin
Time frame: 8 weeks
Insulin Resistance
Using Homeostatic model assessment (HOMA2 calculator which uses fasting plasma glucose and plasma insulin values to calculate insulin resistance)
Time frame: 8 weeks
Serum total cholesterol
Time frame: 8 weeks
Serum triacylglycerol
Time frame: 8 weeks
Serum Low-density lipoprotein (LDL)
Time frame: 8 weeks
Serum High-density lipoprotein (HDL)
Time frame: 8 weeks
Serum Very Low-density lipoprotein (VLDL)
Time frame: 8 weeks
Serum Homocysteine
Time frame: 8 weeks
Serum Adiponectin
Time frame: 8 weeks
Serum Tumor Necrosis Factor (TNF)
Time frame: 8 weeks
Serum Interleukin-6 (IL-6)
Time frame: 8 weeks
Serum C reactive protein (CRP)
Time frame: 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.